Sunday 18 October 2026
Export ATOS’s income statement to Excel — free account
Atossa Therapeutics, Inc.
ATOS Healthcare Biotechnology
In the quarter to June 2026, EPS grew 9.48% and free cash flow fell 32.9%, each against the same quarter a year earlier.
2.91
0.26
+9.81%
Follow ATOS
Atossa Therapeutics, Inc. (ATOS) P/E ratio
Atossa Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.0× (April 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2015 | 0.0× | — |
Against its own ten years
Low 0.0×
High 1.0×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ATOS Atossa Therapeutics, Inc. | n/m |
| IGC IGC Pharma, Inc. compare | n/m |
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ABVC ABVC BioPharma, Inc. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| CYAD Celyad SA compare | n/m |
| IBO Impact Biomedical Inc. compare | 0.2× |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)